Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ribohyal
- Development stage
- Unknown
- Lead developer
- SERVImed Industrial
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
Ribohyal is a patented new chemical entity developed by SERVImed and Iromed for ophthalmic use in the treatment of dry eye disease (DED), including mild to severe cases and photophobia. It consists of hyaluronic acid covalently bound to riboflavin (vitamin B2) at the COOH and OH groups, resulting in a molecule with increased resistance to enzymatic degradation by hyaluronidase compared to standard or cross-linked hyaluronic acids. This modification preserves the mechanical properties of HA while providing longer residence time on the ocular surface and enhanced stability. Ribohyal acts as a lubricant gel that adheres well to the cornea and conjunctiva, supporting tear film stability, epithelial regeneration, hydration, protection from UV light due to riboflavin’s properties, and antioxidant effects. Clinical studies have shown it provides rapid symptom relief for dry eye syndrome with effects lasting up to 8 weeks after instillation[2][4][8]. The product is preservative- and emulsifier-free.
- Brand names
- RibohyalLacrinovaDemoptic BalanceOCUTEIN Ribo-Hyal
- Other names
- HAr 0.1 percentHAr0.1 percentHAr-0.1 percentHyalorib
Beyond the preview
Go deeper on ribohyal.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ribohyal.